Relay Therapeutics (RLAY) Profit After Tax (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Profit After Tax data on file, last reported at -$73.5 million in Q1 2026.

• On a quarterly basis, Profit After Tax rose 3.38% year-over-year to -$73.5 million in Q1 2026; TTM through Mar 2026 was -$272.0 million, a 17.88% increase from a year earlier, with the FY2025 full-year figure at -$274.8 million, up 18.64% from the prior year.
• Profit After Tax for Q1 2026 stood at -$73.5 million, down from -$54.6 million in the prior quarter.
• Over the last five years, Profit After Tax for RLAY reached as high as -$54.6 million in Q4 2025 and fell as low as -$98.5 million in Q2 2023.
• Historically, Profit After Tax has averaged -$77.1 million across 5 years, with a median of -$76.8 million in 2022.
• Across the five-year window, Profit After Tax soared 60.3% in 2022 and sank 51.89% in 2023, its largest moves.
• Year by year, Profit After Tax stood at -$64.5 million in 2022, then fell by 29.38% to -$83.5 million in 2023, then climbed by 5.73% to -$78.7 million in 2024, then surged by 30.57% to -$54.6 million in 2025, then plunged by 34.42% to -$73.5 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$73.5 million in Q1 2026, -$54.6 million in Q4 2025, and -$73.5 million in Q3 2025.